For decades, pancreatic cancer has been one of medicine’s most dangerous threats, and is a diagnosis often delivered with heavy hearts. With a five-year survival rate lingering in the 13-16%, and only 3 percent for patients whose cancer has already spread, the disease has long resisted the advancements transforming other cancer treatments. But today, a wave of scientific momentum surrounding an experimental drug has shifted the outlook to a more optimistic one.
The drug is called daraxonrasib, an oral RAS(ON) inhibitor — a medication that prevents the mutation of the RAS gene — developed by Revolution Medicines. Many researchers believe it may represent one of the most meaningful steps forward for preventing pancreatic cancer. The FDA seems to agree: after reviewing early outcomes, the agency granted daraxonrasib both breakthrough designation and a priority voucher, which are intended to supply promising treatments to patients.
“This is the turning point for the field of pancreatic cancer,” Dr. Brian Wolpin said. Wolpin is the director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farbar Cancer Institute. The institution has been involved in multiple trials to develop the drug and has years of experience surrounding its research. The drug therapy has shown an ability not only to shrink tumors, but also to relieve symptoms that typically deteriorate quickly in patients.
The breakthrough lies in Daraxonrasib’s target: RAS genes, long regarded as “undruggable.” Mutations in the genes lock cells, accelerating the spread of cancer. This changed when a team led by UCSF’s Kevan Shokat pioneered a way to shut down one RAS pathway, leading to the discovery of daraxonrasib.
In a study from Target Oncology, presented at the 2025 Gastrointestinal Cancers Symposium, patients with pancreatic cancer experienced notable benefits with the recommended dose (300 mg). In broader groups, disease control rates apparoached 95%. The most compelling evidence for the success of the drug, however, comes from individual stories. Debby Orcutt’s tumor shrank by 64% after daraxonrasib treatment.
Recognizing the drug’s potential, the FDA selected daraxonrasib for its Commissioner’s National Priority Voucher, a pathway capable of accelerating a drug review from a year down to mere weeks. The initiative aims to fast-track therapies that address national health priorities, including diseases with long-standing gaps in effective treatment.
Regulatory expert Dan Kracov warned that the program must be closely monitored to ensure speed does not compromise safety. Still, the enthusiasm of the FDA’s oncology team signals a level of institutional confidence not often seen with early-stage oncology agents.
Revolution Medicines is now rapidly enrolling participants in a study comparing daraxonrasib with standard chemotherapy. Goldsmith has previously stated the company expects major developments in 2026, alluding to the next step toward getting therapy to patients as soon as possible.
Physicians emphasize that daraxonrasib is not a cure and comes with side effects, most notably skin reactions. Still, for many people who started these trials with little hope, Daraxonrasib has delivered something measurable: more time. For the first time in years, researchers believe the field is standing at the edge of something bigger, a growing possibility that one of medicine’s deadliest diagnoses may soon have a treatment capable of transforming lives.
